When will GABA Therapeutics IPO?

Management intends to IPO once it completes Phase 1 and its proof-of-concept study to demonstrate efficacy. Data gathered measuring GRX-917’s ability to increase neurosteroids, along with efficacy data, should provide for a highly anticipated public offering.

2019-09-22T19:32:25+00:00|